Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes-Reference-Cited by-同舟云学术

Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes

Published:2002-03 Issue:3 Volume:68 Page:180-186
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Wallvik Jonas,Stenke Leif,Bernell Per,Nordahl Gunnar,Hippe Erik,Hast Robert

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1034/j.1600-0609.2002.01530.x/fullpdf

Reference26 articles.

1. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes;Stenke;Leukemia,1993

2. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes;Stein;Blood,1991

3. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin;Bowen;Br J Haematol,1991

4. High-dose recombinant human erythropoietin for treatment of anaemia in myelodysplastic syndromes and paroxysmal noctural hemoglobinuria: a pilot study;Stebler;Exp Hematol,1990

5. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes [see comments];Ferrini;Br J Haematol,1998

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies;Trends in Molecular Medicine;2021-10

2. Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis;European Journal of Haematology;2021-04-14

3. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion;Annals of Hematology;2019-10-25

4. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents;Journal of Clinical Oncology;2016-09-01

5. Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis;Oncotarget;2016-04-26